Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anil Mandhani is active.

Publication


Featured researches published by Anil Mandhani.


BJUI | 2002

Prospective evaluation of safety and efficacy of the supracostal approach for percutaneous nephrolithotomy

R. Gupta; Anant Kumar; R. Kapoor; A Srivastava; Anil Mandhani

Objective  To prospectively evaluate the safety and efficacy of the supracostal approach for percu‐taneous nephrolithotomy (PCNL), as it is usually avoided because of concerns about potential chest complications.


BJUI | 2005

Buccal mucosal urethroplasty: a versatile technique for all urethral segments

Deepak Dubey; Anant Kumar; Anil Mandhani; Aneesh Srivastava; Rakesh Kapoor; Mahendra Bhandari

Authors from India describe their experience in a series of patients with bulbar urethral strictures in whom they used a buccal mucosal graft. They found this to be the most versatile substitute.


BJUI | 2005

Genetic polymorphism of glutathione S‐transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India

Daya Shankar Lal Srivastava; Anil Mandhani; Balraj Mittal; Rama Devi Mittal

To examine the association of glutathione‐S‐transferase (GST) gene polymorphisms in patients with sporadic prostate cancer, in a North Indian population, as GSTs are active in detoxifying a wide variety of endogenous or exogenous carcinogens, and genetic polymorphisms of GSTM1, GSTT1 and GSTP1 have been assessed to evaluate the relative risk of various cancers.


Journal of Endourology | 2003

Routine stenting after ureteroscopy for distal ureteral calculi is unnecessary: results of a randomized controlled trial.

Aneesh Srivastava; Rajshekhar Gupta; Anant Kumar; Rakesh Kapoor; Anil Mandhani

BACKGROUND AND PURPOSE Insertion of a ureteral stent is routinely done after ureteroscopy. Recently, several authors have questioned routine stenting after ureteroscopy for distal ureteral stones. We report our results of a randomized study comparing ureteroscopy with and without placement of stents for distal ureteral stones. PATIENTS AND METHODS A total of 48 patients undergoing ureteroscopy for distal ureteral stones were randomized to a stented group (N = 26) or a nonstented group (N = 22). Ureteroscopy was carried out with Wolf 8.5F semirigid endoscope, and the Swiss Lithoclast was used as the source of energy. Any stent was removed at 3 weeks. Patients were assessed for success, operative time, postoperative pain score, analgesic requirement, stent-related symptoms, and risk of ureteral stricture formation. Baseline variables were not significantly different in the two groups. RESULTS There was no significant difference in the two treatment groups with regard to need for ureteral dilation, use of intracorporeal lithotripsy, or occurrence of intraoperative and postoperative complications. A successful outcome was achieved in 100% of both groups. The mean pain score on day 0 was 5.23 +/- 0.95 of 10 in the stented group and 4.82 +/- 0.96 in the nonstented group; this difference was not statistically significant. Similarly, the analgesic requirement in the two treatment groups was not significantly different. However, patients with stents had significantly more pain (including flank pain with voiding: P = 0.01), urgency (P = 0.04) and dysuria (P <0.01). Radiologic follow-up was available for 83.33% of the patients at the 3-month visit. None of the patients had evidence of ureteral stricture or residual stone fragments. CONCLUSION In select patients undergoing ureteroscopy for distal ureteral stones, stents can be safely omitted. Patients without stents have significantly fewer lower-urinary symptoms of pain, urgency, and dysuria and are not at risk of increased complications. Avoiding stents may be particularly cost effective in developing countries.


The Journal of Urology | 1999

MANAGEMENT OF FUNCTIONAL BLADDER NECK OBSTRUCTION IN WOMEN: USE OF α-BLOCKERS AND PEDIATRIC RESECTOSCOPE FOR BLADDER NECK INCISION

Anant Kumar; Anil Mandhani; Sanjay Gogoi; Aneesh Srivastava

PURPOSE Functional bladder neck obstruction has been definitively diagnosed in the last few years due to detailed synchronous pressure flow, electromyography and video urodynamics. Clean intermittent self-catheterization and bladder neck incision are the modalities of treatment. To our knowledge the role of alpha-blockers is not yet defined in women. A new technique was developed to perform bladder neck incision using a pediatric resectoscope. MATERIALS AND METHODS A total of 24 women with obstructive voiding symptoms or retention were evaluated with video pressure flow electromyography, and diagnosed with functional bladder neck obstruction due to high pressure and low flow on silent electromyography and bladder neck appearance on fluoroscopy. Patients were initially treated with clean intermittent self-catheterization and alpha-blockers. Catheterization was stopped when post-void residual was less than 50 ml. and only alpha-blocker therapy was continued. Bladder neck incision was performed in patients who had a poor response to or side effects of alpha-blocker therapy, or when therapy was discontinued due to economic reasons. Clean intermittent self-catheterization was continued in patients who had a poor response to alpha-blockers or refused to undergo bladder neck incision. Bladder neck incision was performed in the initial 2 cases with an adult resectoscope using a Collins knife and subsequently a pediatric resectoscope (13F). Uroflow and post-void residual measurements were performed in all cases. RESULTS Of the 24 patients 12 (50%) showed improvement in symptoms, peak flow and post-void residual (p <0.01) with alpha-blocker therapy only. Of the 12 patients who had a poor response to alpha-blockers 6 underwent bladder neck incision subsequently and 6 remained on clean intermittent self-catheterization. All 8 patients treated with bladder neck incision, including 2 who had a good response but discontinued alpha-blocker therapy, had sustained improvement in post-void residual and peak flow (p <0.01) after a mean followup of 3.8 +/- 2.4 years. Grade 1 stress incontinence in 2 adult resectoscope cases responded to conservative treatment. None of the pediatric resectoscope cases had stress incontinence. CONCLUSIONS Clean intermittent self-catheterization and alpha-blockers are the initial treatment options for functional bladder neck obstruction. The alpha-blockers were successful in 50% of our patients. Bladder neck incision should be offered judiciously with minimal risk of curable stress incontinence. The pediatric resectoscope is useful to make a well controlled incision safely in the female urethra.


BJUI | 2003

Substitution urethroplasty for anterior urethral strictures: a critical appraisal of various techniques

Deepak Dubey; Anant Kumar; P. Bansal; A Srivastava; R. Kapoor; Anil Mandhani; Mahendra Bhandari

To retrospectively compare the outcome of various techniques of substitution urethroplasty.


Mutation Research-genetic Toxicology and Environmental Mutagenesis | 2009

Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population?

Ruchika Gangwar; Dinesh Ahirwar; Anil Mandhani; Rama Devi Mittal

OBJECTIVE Polymorphisms in DNA repair genes may be associated with altered DNA repair capacity, thereby influencing an individuals susceptibility to smoking-related cancers such as bladder cancer. Therefore, we sought to examine the correlation between single nucleotide polymorphisms in DNA repair genes and bladder cancer. METHODOLOGY We undertook a case-control study of 212 urothelial bladder cancer (UBC) cases and 250 controls to investigate the association between OGG1 (C1245G rs1052133), XRCC3 (C18067T, rs861539) and XRCC7 (G6721T, rs7003908) polymorphisms and bladder cancer susceptibility by PCR-RFLP and the ARMS method. We also investigated gene-environment interactions. RESULTS The OGG1 GG genotype was associated with an elevated risk of urothelial bladder cancer (UBC) (OR, 2.10; p, 0.028). XRCC7 + 6721 GG was also associated with increased susceptibility to UBC (OR, 4.45; p, 0.001). In a recessive model, the OGG1 GG genotype showed an increased risk of TaG(2,3) + T1G(1-3) tumors. Additionally, the OGG1 GG genotype in non-smokers represented a 2.46-fold greater risk (OR, 2.46; p, 0.035) in bladder cancer patients. Subsequent analysis demonstrated more pronounced association of XRCC7 with smokers (OR, 4.39; p, 0.001). XRCC7 also showed increased association with TaG(2,3) + T1G(1-3) tumors and muscle invasive tumors (OR, 3.16; p, 0.001 and OR, 4.24; p, 0.001, respectively). Multiple Cox regression analysis in non-muscle invasive bladder tumor (NMIBT) patients demonstrated an association of the OGG1 GG polymorphism with a high risk of recurrence in patients on cystoscopic surveillance (HR, 4.04; p, 0.013). Subsequently, shorter recurrence-free survival (log rank p, 0.024; CC/GG, 42/24) was observed. CONCLUSION Our data suggest association of a variant (GG) genotype of OGG1 with increased UBC susceptibility and a high risk of tumor recurrence in NMIBT patients on cystoscopic surveillance. XRCC7 G allele carriers (TG+GG) are also at an elevated risk for susceptibility to UBC as evidenced by a high odds ratio throughout the analysis.


Cancer Genetics and Cytogenetics | 2008

Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer

Dinesh Ahirwar; Pravin Kesarwani; Parmeet Kaur Manchanda; Anil Mandhani; Rama Devi Mittal

Cytokines mediate many immune and inflammatory responses contributing to tumorigenesis. The present study evaluated polymorphisms of IL4, IL6, and TNF (previously TNFA) genes influencing risk in development of transitional cell carcinoma of bladder and recurrence after bacillus Calmette-Guérin (BCG) immunotherapy. The study included 136 unrelated histopathologically confirmed cases and 200 population-based controls. Genomic DNA was extracted from peripheral leukocytes and genotyped for polymorphism in IL4 intron 3, with point mutations identified by amplification refractory mutation system polymerase chain reaction (ARMS-PCR) in IL6-174 G/C and by PCR-restriction fragment length polymorphism analysis in TNF-308 G/A. The IL6 variant C/C exhibited significant association with bladder cancer risk (odds ratio OR = 2.811, P = 0.004), but IL4 and TNF genetic variants did not. Significant association was observed for IL4 (B1/B2+B2/B2) with high-grade or late-stage tumor for TaG3+T1 and T2+ (OR = 5.950, and 6.342 respectively) and with smoking (P = 0.004, OR = 4.202). Low recurrence risk was observed in BCG-treated patients carrying C/C genotype of IL6 (hazard ratio = 0.298, P = 0.03), and also higher recurrence-free survival (log rank P = 0.021). TNF and IL4 demonstrated no association of bladder cancer risk and BCG therapy. The low-producing variant C/C of IL6 may be a risk factor for bladder cancer, whereas high-producing genotypes of IL4 (B1/B2+B2/B2) may predispose to higher risk in patients with high-grade or late-stage tumor and smoking habits. The low-producing C/C IL6 genotype, which favors Th1 response, may be a beneficial prognostic indicator for treatment and survival of BCG-treated patients.


The Journal of Urology | 2002

Urinary Interleukin-8 Predicts the Response of Standard and Low Dose Intravesical Bacillus Calmette-Guerin (Modified Danish 1331 Strain) for Superficial Bladder Cancer

Anant Kumar; Deepak Dubey; Pradeep Bansal; Anil Mandhani; Sita Naik

PURPOSE We determined whether the proinflammatory cytokine interleukin-8 (IL-8) can serve as a predictor for the response to standard (120 mg.) and low (40 mg.) dose intravesical bacillus Calmette-Guerin (BCG) (modified Danish 1331 strain) for managing superficial bladder cancer in patients at risk for recurrence and progression. MATERIALS AND METHODS We randomized 26 patients with superficial bladder cancer to receive a 6-week course of standard dose 120 mg. or low dose 40 mg. intravesical BCG. Voided urine samples were collected immediately before and after (2 and 4 hours) BCG instillation. Urine samples were centrifuged at 1,500 rpm for 8 minutes and stored at -80C. IL-8 was measured using a commercial enzyme-linked immunosorbent assay. Patients were monitored for recurrence, progression and side effects of BCG treatment at 3-month intervals. RESULTS At a median followup of 24 months (range 12 to 30), 5 and 6 patients who received a standard and low dose, respectively had disease recurrence and/or progression (nonresponders). At 4 hours after BCG mean Il-8 levels plus or minus SD were significantly higher in responders than in nonresponders (1,099.33 +/- 708.51 versus 261.82 +/- 182.66 pg./ml., p = 0.001). There was no difference at 4 hours in mean IL-8 levels in the standard and low dose groups (596.92 +/- 546 and 893 +/- 798.67 pg./ml., respectively, p = 0.28). In all patients who remained disease-free IL-8 levels were greater than 400 pg./ml. In 9 of the 11 patients with disease recurrence/progression IL-8 levels were less than 400 pg./ml. CONCLUSIONS IL-8 secretion after the initial intravesical BCG instillation strongly correlates with the possibility of future recurrence/progression. The quantitative IL-8 response to low and standard dose intravesical BCG (Danish 1331) is similar.


BJUI | 2010

Predictive factors for mortality and need for nephrectomy in patients with emphysematous pyelonephritis

Rakesh Kapoor; K Muruganandham; Anil Gulia; Manish Singla; Saurabh Agrawal; Anil Mandhani; M.S. Ansari; Aneesh Srivastava

Study Type – Therapy (case series)
Level of Evidence 4

Collaboration


Dive into the Anil Mandhani's collaboration.

Top Co-Authors

Avatar

Rakesh Kapoor

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Aneesh Srivastava

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Anant Kumar

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Deepak Dubey

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Rama Devi Mittal

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

R. Kapoor

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

A Srivastava

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Pratipal Singh

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

M.S. Ansari

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Dinesh Ahirwar

Sanjay Gandhi Post Graduate Institute of Medical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge